Business Wire

First Eagle Expands Offering of US Small Cap Strategy to Non-US Investors

21.9.2022 16:00:00 EEST | Business Wire | Press release

Share

First Eagle Investments (“First Eagle”) today announced it has expanded its portfolio offerings to non-US investors through the launch of its US Small Cap strategy within First Eagle’s Irish UCITS platform. The sub-fund, which was seeded by First Eagle in February 2022, pursues an opportunistic small cap value strategy. It invests in companies that the portfolio management team believes are attractively valued and have the potential to benefit from a catalyst—such as new management, a more favorable business cycle, product innovation and/or margin improvement—that may drive a recovery in earnings growth.

The strategy is managed by First Eagle’s Small Cap team, which was formed in April 2021 with the hiring of Portfolio Manager Bill Hench, Associate Portfolio Managers Suzanne Franks and Rob Kosowsky, and Senior Research Analyst Adam Mielnik. All four were previously employed by Royce Investment Partners, where they managed the portfolios of a US mutual fund, a UCITS fund and a collective investment trust, with Hench listed as one of the portfolio managers since 2004. Subsequently, the Small Cap team added Trader/Analyst Mark Salamone and Analyst Connor Sheehy in October 2021 and July 2022, respectively.

“We believe skilled active managers can exploit the ample inefficiencies in the US small cap market to deliver differentiated investment solutions,” said Matthieu Louanges, Global Head of Institutional and International Wealth Management at First Eagle. “Bill and his team have been focused on the US small cap market for many years, and our London and Munich-based account management teams are pleased to offer existing and prospective clients access to this time-tested, value-oriented strategy through a UCITS structure.”

First Eagle’s US Small Cap strategy takes an opportunistic but disciplined approach to bottom-up portfolio construction, employing in-house fundamental research in an effort to identify companies that appear temporarily mispriced by the market due to inefficiently valued assets, turnaround potential, accelerating-but-overlooked earnings growth, or unacknowledged market leadership. True small cap specialists, the team typically holds 180 to 300 stocks—including microcap stocks with market capitalizations below $1 billion—in pursuit of broad diversification at the security level.

“Small cap stocks represent a particularly volatile and inefficiently priced segment of the US equity market,” said Hench. “However, these dynamics historically also have created opportunities for disciplined active managers to generate attractive long-term returns for investors through diversified portfolios of undervalued small cap names. We are excited to offer our expertise in this space to investors outside the US.”

The US Small Cap strategy is offered through a sub-fund of First Eagle’s Irish UCITS vehicle, with three types of share classes (retail, advisory and institutional) denominated in three currencies (US dollars, euros and British pounds). The UCITS fund currently is available for public offer and sale in Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Portugal and Spain, and is available for eligible investors in Switzerland and the United Kingdom. First Eagle plans to register the UCITS fund for distribution in additional countries in the near future. This latest sub-fund joins First Eagle’s growing UCITS platform, which was established in May 2021 with the launch of a sub-fund offering its International Value (global excluding the US) strategy.

About First Eagle Investments

First Eagle Investments is an independent, privately owned investment management firm headquartered in New York with approximately $101.6 billion in assets under management as of June 30, 2022. (On a pro forma basis to include the recent acquisition of Napier Park Global Capital, First Eagle’s total assets under management are approximately $121.1 billion as of that same date.) Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside mitigation. With a heritage dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.firsteagle.com.

The total pro forma assets under management (AUM) represents the combined AUM of First Eagle Investments and Napier Park Global Capital as of June 30, 2022. It includes $1.5 billion of committed and other non-fee-paying capital from First Eagle Alternative Credit and $0.9 billion of committed and other non-fee-paying capital from Napier Park, inclusive of assets managed by Regatta Loan Management LLC. Pro forma results are for illustrative purposes only and are not actual performance results. The pro forma results reflect a business combination that had not yet taken place and may differ materially from actual performance results.

IMPORTANT INFORMATION FOR INVESTORS

This is a marketing communication. The material is for informational purposes only and should not be regarded as a recommendation or an offer to buy or sell any product or service to which this information may relate. Certain products and services may not be available to all entities or persons. This release does not constitute or contain an offer, solicitation, recommendation or investment advice with respect to the purchase of any sub-fund described herein or any security.

The investment vehicle referenced in this material has been established as an Irish collective asset-management vehicle with variable capital constituted as an umbrella fund with segregated liability between its sub-funds under the laws of Ireland (registered number 445369) (the “ICAV”). Prospective investors should carefully consider a sub-fund’s objectives, risks, charges, tax considerations and expenses and other relevant information before investing. For this and more information on the ICAV, please refer to the ICAV’s prospectus, the supplement for the sub-funds and the applicable KIIDs and read them carefully before you invest and before making any final investment decisions. This is not a contractually binding document; do not base any final investment decision on this communication alone.

An investment in a sub-fund involves risk; principal loss is possible. There is no guarantee a sub-fund’s investment objectives will be achieved. In respect of the US Small Cap strategy, investments in small and micro-size companies historically have been more volatile in price than larger company securities, especially over the short term. Positions in small and micro-size companies also may be more difficult or expensive to trade. Among the reasons for the greater price volatility are the less certain growth prospects of small and micro-size companies, the lower degree of liquidity in the markets for such securities, and the greater sensitivity of small and micro-size companies to changing economic conditions. Value investments present the risk of never reaching what may be believed to be their full market values or may decline in value.

More information on these risk considerations, as well as information on other risks to which the sub-fund is subject, such as liquidity, market, and investment strategy risks, are included in the ICAV’s prospectus.

The ICAV’s prospectus is available on the First Eagle website and www.fundinfo.com. The KIIDs can also be accessed on the First Eagle website and are available in one of the official languages of each of the EU Member States into which the sub-funds have been notified for marketing under the UCITS Directive 2009/65/EC.

Prospective investors should also consult their professional advisers as to the suitability of any investment in light of their particular circumstances and applicable citizenship, residence or domicile. The ICAV has been authorized in Ireland as a UCITS pursuant to the European Communities (Undertakings for Collective Investments in Transferable Securities) Regulation 2011, as amended.

Shares of the ICAV are only available for certain non-US persons in select transactions outside the United States, or, in limited circumstances, otherwise in transactions that are exempt from the registration requirements of the United States Securities Act of 1933, as amended, and such other US laws as may be applicable.

The ICAV currently is available for public offer and sale in Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Portugal and Spain, and is available for eligible investors in Switzerland and the United Kingdom, in each case in accordance with applicable law.

The views expressed herein represent the opinions of First Eagle and are not intended as a forecast or guarantee of future results for any product or service.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Mount and Nadler
Hedda Nadler
hedda@mountandnadler.com
212.759.4440

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

MariaDB Launches into the Agentic Era with an Agent-Ready Platform and a Bold New Brand4.11.2026 15:00:00 EET | Press release

MariaDB plc, the Unified Open Database Platform for the Agentic Enterprise, today announced MariaDB Enterprise Platform 2027, a release that delivers 56% higher peak throughput¹, stronger resilience for multi-region deployments and faster ways to build and run AI agents. What began as an open source operational database now spans mission-critical transactions, real-time analytics, in-memory speed, AI tooling and multi-region scale on one unified platform. The new brand identity unveiled alongside it shows where the company is headed, powering the AI-driven enterprise with the world’s most trusted database platform. Every AI agent in production is betting that the data in front of it is true. In most enterprises, that data is spread across multiple operational databases, a warehouse, vector stores, ETL engines and caches, and every integration between them adds latency, sync lag and another point of failure. The pressure is about to multiply. IDC predicts that by 2027, G2000 [the world’

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye